New cancer drug AXT-1003 enters first human safety trial
Disease control
Recruiting now
This early-stage study tests a new drug called AXT-1003 in people with advanced non-Hodgkin lymphoma or solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. About 78 participants will be enrolled.
Phase: PHASE1 • Sponsor: Axter Therapeutics (Beijing) Co., Ltd • Aim: Disease control
Last updated May 17, 2026 01:59 UTC